Cleveland BioLabs
Market Cap
US$54.1m
Last Updated
2021/01/21 23:57 UTC
Data Sources
Company Financials
Executive Summary
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. More Details
Risk Analysis
Snowflake Analysis
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Cleveland BioLabs's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CBLI is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: CBLI's weekly volatility has decreased from 43% to 11% over the past year.
Market Performance
7 Day Return
11.2%
CBLI
0.7%
US Biotechs
1.4%
US Market
1 Year Return
271.4%
CBLI
40.9%
US Biotechs
22.6%
US Market
Return vs Industry: CBLI exceeded the US Biotechs industry which returned 41.5% over the past year.
Return vs Market: CBLI exceeded the US Market which returned 22.8% over the past year.
Shareholder returns
| CBLI | Industry | Market | |
|---|---|---|---|
| 7 Day | 11.2% | 0.7% | 1.4% |
| 30 Day | 29.7% | 5.2% | 4.9% |
| 90 Day | 56.2% | 23.7% | 14.6% |
| 1 Year | 271.4%271.4% | 43.2%40.9% | 25.4%22.6% |
| 3 Year | 8.2%8.2% | 27.1%20.5% | 46.8%37.0% |
| 5 Year | 10.0%10.0% | 58.4%46.0% | 132.0%106.1% |
Long-Term Price Volatility Vs. Market
How volatile is Cleveland BioLabs's share price compared to the market and industry in the last 5 years?
Simply Wall St News
11 months ago | Simply Wall St
Could The Cleveland BioLabs, Inc. (NASDAQ:CBLI) Ownership Structure Tell Us Something Useful?1 year ago | Simply Wall St
Does The Cleveland BioLabs, Inc. (NASDAQ:CBLI) Share Price Tend To Follow The Market?1 year ago | Simply Wall St
Does Cleveland BioLabs, Inc.'s (NASDAQ:CBLI) CEO Pay Matter?Valuation
Is Cleveland BioLabs undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Cleveland BioLabs is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cleveland BioLabs has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Next Steps
- Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.
Future Growth
How is Cleveland BioLabs forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
20.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cleveland BioLabs has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Cleveland BioLabs's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Cleveland BioLabs performed over the past 5 years?
19.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CBLI is currently unprofitable.
Growing Profit Margin: CBLI is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CBLI is unprofitable, but has reduced losses over the past 5 years at a rate of 19.6% per year.
Accelerating Growth: Unable to compare CBLI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBLI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: CBLI has a negative Return on Equity (-88.69%), as it is currently unprofitable.
Next Steps
Financial Health
How is Cleveland BioLabs's financial position?
Financial Position Analysis
Short Term Liabilities: CBLI's short term assets ($3.2M) exceed its short term liabilities ($483.9K).
Long Term Liabilities: CBLI has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: CBLI is debt free.
Reducing Debt: CBLI has no debt compared to 5 years ago when its debt to equity ratio was 14.3%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBLI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: CBLI has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 30.8% each year.
Next Steps
Dividend
What is Cleveland BioLabs's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBLI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBLI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBLI's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBLI's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBLI's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.0yrs
Average management tenure
CEO
Christopher Zosh (45 yo)
1.08yrs
Tenure
US$103,494
Compensation
Mr. Christopher Zosh has been the Interim Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer of Cleveland BioLabs, Inc. since December 13, 2019 and has been its Vice ...
CEO Compensation Analysis
Compensation vs Market: Christopher's total compensation ($USD103.49K) is below average for companies of similar size in the US market ($USD533.25K).
Compensation vs Earnings: Christopher's compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| VP of Finance | 1.08yrs | US$103.49k | no data | |
| Chief Scientific Officer | 17.58yrs | US$66.14k | 0.57% $ 308.0k | |
| Chief Medical Officer | 6yrs | US$73.73k | 0% $ 0 |
6.0yrs
Average Tenure
64yo
Average Age
Experienced Management: CBLI's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 4.5yrs | US$35.00k | 0.0010% $ 568.5 | |
| Independent Director | 5.5yrs | no data | no data | |
| Independent Director | 4.5yrs | no data | no data | |
| Independent Chair of the Board | 4.5yrs | US$35.00k | no data | |
| Independent Director | 4.5yrs | no data | no data | |
| Independent Director | 2.42yrs | no data | no data |
4.5yrs
Average Tenure
40yo
Average Age
Experienced Board: CBLI's board of directors are considered experienced (4.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18%.
Top Shareholders
Company Information
Cleveland BioLabs, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Cleveland BioLabs, Inc.
- Ticker: CBLI
- Exchange: NasdaqCM
- Founded: 2003
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$54.146m
- Shares outstanding: 13.34m
- Website: https://www.cbiolabs.com
Number of Employees
Location
- Cleveland BioLabs, Inc.
- 73 High Street
- Buffalo
- New York
- 14203
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CBLI | NasdaqCM (Nasdaq Capital Market) | Yes | Common Stock | US | USD | Jul 2006 |
| 7CB1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jul 2006 |
Biography
Cleveland BioLabs, Inc., a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/21 23:57 |
| End of Day Share Price | 2021/01/21 00:00 |
| Earnings | 2020/09/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.